Drug intelligence / Profile preview

NNC0113-6856

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

NNC0113-6856 is an investigational oral medication being developed for type 2 diabetes mellitus. It functions as a prodrug that is slowly converted in the body to semaglutide, a GLP-1 receptor agonist. Semaglutide is a substance similar to a hormone in the body that helps improve blood sugar control. The drug is being developed by Novo Nordisk and is currently in early clinical development stages.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NNC0113-6856.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0113-6856.

Explore the full profile